D4S0 Stock Overview
Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for D4S0 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥25.60 |
| 52 Week High | JP¥29.80 |
| 52 Week Low | JP¥25.00 |
| Beta | 0.26 |
| 1 Month Change | -3.76% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| D4S0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.8% | -2.5% | -2.6% |
| 1Y | n/a | -15.6% | 6.9% |
Return vs Industry: Insufficient data to determine how D4S0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how D4S0 performed against the German Market.
Price Volatility
| D4S0 volatility | |
|---|---|
| D4S0 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D4S0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine D4S0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 18,726 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Daiichi Sankyo Company, Limited Fundamentals Summary
| D4S0 fundamental statistics | |
|---|---|
| Market cap | €50.59b |
| Earnings (TTM) | €1.53b |
| Revenue (TTM) | €10.78b |
33.0x
P/E Ratio4.7x
P/S RatioIs D4S0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D4S0 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.76t |
| Cost of Revenue | JP¥419.99b |
| Gross Profit | JP¥1.34t |
| Other Expenses | JP¥1.09t |
| Earnings | JP¥250.40b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 132.94 |
| Gross Margin | 76.11% |
| Net Profit Margin | 14.24% |
| Debt/Equity Ratio | 6.3% |
How did D4S0 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield46%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 22:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daiichi Sankyo Company, Limited is covered by 32 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| null null | BNP Paribas Securities (Asia) |
| Koichi Mamegano | BofA Global Research |